Table of Contents
ISRN Dermatology
Volume 2011 (2011), Article ID 549870, 16 pages
Review Article

Biologicals and Fetal Cell Therapy for Wound and Scar Management

1Cellular Therapy Unit, Department of Musculoskeletal Medicine, University Hospital of Lausanne, CHUV/UNIL, PAV 03, 1011 Lausanne, Switzerland
2Office of Dermatology and Angiology, Place Benjamin Constant 2, 1005 Lausanne, Switzerland
3Department of Plastic and Reconstructive Surgery, University Hospital of Lausanne, CHUV/UNIL, BH 10, 1011 Lausanne, Switzerland
4Department of Pediatric Surgery, University Hospital of Lausanne, CHUV/UNIL, BH 10, 1011 Lausanne, Switzerland
5Biomechanical Orthopedics Laboratory, Swiss Federal Institute of Technology, EPFL, 1015 Lausanne, Switzerland

Received 27 January 2011; Accepted 16 March 2011

Academic Editors: B. Amichai, B. Gesser, D. V. Messadi, E. Pasmatzi, and A. Zalewska

Copyright © 2011 Nathalie Hirt-Burri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management.